Melior Pharmaceuticals awarded grant for advancing pulmonary therapeutic in Covid-19 phase 2 clinical trial

This article was originally published here

The planned study is intended to recruit 428 subjects who were recently diagnosed with COVID-19, have early symptoms, but are not hospitalized. Tolimidone is expected to significantly mitigate

The post Melior Pharmaceuticals awarded grant for advancing pulmonary therapeutic in Covid-19 phase 2 clinical trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply